

Company Overview

Kane Biotech is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms.

Kane Biotech Announces Third Quarter 2018 Financial Results

Nov 14 2018, 6:09 PM EST

Kane Biotech Announces Extension of Warrants

Nov 12 2018, 4:30 PM EST

Kane Biotech Records Significant Online Sales Growth from Amazon

Nov 9 2018, 8:30 AM EST

Stock Overview

| | |
|------------|----------------------|
| Symbol | KNBIF |
| Exchange | OTCQB |
| Market Cap | 6.4m |
| Last Price | \$0.0799 |
| 52-Week | \$0.0449 - \$0.08394 |

11/06/2018 12:53 PM EST

Investor Relations

Edison Advisors
Tirth Patel
Vice President, Investor Relations
295 Madison Avenue, 18th Floor
New York, NY 10017
T: 646-653-7035
M: 386-295-2215
tpatel@edisongroup.com

Management Team

Marc Edwards

Director, Interim Chief Executive Officer

Ray Dupuis

Chief Financial Officer

Gordon Guay, Ph.D.

Chief Scientific Officer

Grant Humphrey

Vice President, Sales

Nanda Yakandawala

Senior Research Scientist

Wendy Nachtigall

Director, Marketing

Andrea Gordon

Director, Regulatory and Quality Control

Kane Biotech Inc.

162-196 Innovation Drive
Winnipeg, Manitoba R3T 2N2
Canada

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.